For suitable patients, telemedicine consultations may also provide a convenient way to discuss weight management options, review eligibility, and receive ongoing medical follow-up where clinically appropriate
Is it useful for IBS or IBD
Impurity profiling of the most frequently encountered falsified polypeptide drugs on the Belgian market
Morning vs
Electrolytes address the salt deficit driving nausea
UHCs typical prior authorization requirements for Wegovy and Zepbound include: BMI documentation A documented BMI of 30 or higher, or BMI of 27 or higher with at least one weight-related comorbidity such as type 2 diabetes, hypertension, dyslipidemia, or obstructive sleep apnea Comorbidity evidence Clinical records documenting the specific comorbidities that support the medical necessity of treatment Supervised weight management history Evidence of participation in a structured weight management program, which may include diet, exercise, and behavioral counseling, typically for 3 to 6 months prior to the request Prescriber qualifications The prescriber must be a physician, nurse practitioner, or physician assistant with appropriate prescribing authority UHC reviews prior authorizations against specific clinical policy bulletins